Provided are methods for preparing T cells for cell therapy, compositionsproduced by the methods, and methods ofadministering the cells to subjects. In particular, the disclosure relates topreparation of engineered T cells, such as those expressinggenetically engineered receptors, such as genetically engineered antigenreceptors such as engineered (recombinant) TCRs and chimericantigen receptors (CARs), or other recombinant chimeric receptors. Features ofthe methods include producing a more consistentand/or predictable T cell product and/or lower toxicity compared with othermethods. The provided methods include incubating cells understimulating conditions to induce expansion or proliferation of naive-like Tcells compared to non-naive like T cells in the stimulatedcomposition, which in turn can result in preferential transduction of cellsderived from the naive-like T cells. Features of the methodscan also include reduction in costs, numbers of steps, and resourceexpenditure compared with other methods
